Regarding the metformin combination, a retrospective clinical study explored advanced-stage NSCLC patients with T2DM harboring EGFR mutations such as L858R and 19del who received either concurrent metformin or other hypoglycemic drugs with EGFR-TKIs treatment [74]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.